Horn Margaret A 4
Research Summary
AI-generated summary
Revolution Medicines (RVMD) COO Margaret Horn Sells Shares
What Happened
Margaret A. Horn, Chief Operating Officer of Revolution Medicines (RVMD), sold 4,583 shares in an open-market transaction on March 17, 2026, at $99.48 per share for total proceeds of $455,919. This was a sale (not a purchase), commonly a routine liquidity or tax-related transaction rather than a direct bullish signal on the company.
Key Details
- Transaction date and price: March 17, 2026 — 4,583 shares sold at $99.48 each (total $455,919).
- Transaction type/code: Open-market sale (S).
- Shares owned after transaction: Filing notes holdings "include 73,050 RSUs" (per footnote); the filing excerpt provided does not specify the total exact post-transaction share count.
- Footnotes: F1 — Sale executed pursuant to a Rule 10b5-1 instruction letter (adopted May 31, 2023) to satisfy the reporting person's tax withholding obligation upon vesting of RSUs after July 15, 2023. F2 — Holdings include 73,050 restricted stock units (RSUs).
- Filing timeliness: Report filed March 19, 2026; this appears to be within the Form 4 two-business-day reporting window for the March 17 transaction.
Context
Because the sale was made under a pre-established Rule 10b5-1 plan to cover tax withholding on vested RSUs, it is generally considered a routine, administrative transaction rather than an expression of new sentiment by the insider. For retail investors, purchases by insiders tend to signal more informative conviction than routine sales; this filing should be viewed in that context.